Literature DB >> 477707

Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension.

O L Pedersen, E Mikkelsen, N J Christensen, H J Kornerup, E B Pedersen.   

Abstract

Acute sublingual administration of nifedipine 10--20 mg to 13 hypertensive patients caused a rapid decrease in blood pressure (BP) and a concomitant increase in heart rate (HR), plasma noradrenaline (NA) and plasma renin activity (PRA); there was no significant change in plasma adrenaline (A) or aldosterone (ALDO). Basal PRA was the major determinant of the rise in PRA, as a close correlation was present between the basal value and the increase caused by nifedipine (r = 0.92), p less than 0.001). The rise in PRA was also correlated with the plasma concentration of nifedipine after 60 min (r = 0.80, p less than 0.01), but it was not correlated with the decrease in BP, the rise in HR or the increase in NA. Nifedipine 30--60 mg daily for 6 weeks caused a reduction in mean BP from 133 to 113 mmHg (p less than 0.001). Body weight and serum potassium decreased but no consistent change was noted in NA, PRA, ALDO or 24 h-excretion of catecholamines. A significant correlation was present between the change in NA and that in PRA (r = 0.74, p less than 0.01). The alterations in the various parameters in the acute and chronic studies were not correlated. The findings indicate that different regulatory mechanisms are activated during acute and chronic administration of nifedipine. It is suggested that an initial rise in sympathetic activity gradually decreases during prolonged therapy, but it still remains a determinant of PRA.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 477707     DOI: 10.1007/bf00618511

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

Review 1.  Vasodilator drugs in the treatment of hypertension.

Authors:  J Koch-Weser
Journal:  Arch Intern Med       Date:  1974-06

2.  Aldosterone biosynthesis. Interrelationship of regulatory factors.

Authors:  G H Williams; R G Dluhy
Journal:  Am J Med       Date:  1972-11       Impact factor: 4.965

3.  Plasma renin concentration measured by use of radioimmunoassay for angiotensin I.

Authors:  J Giese; M Jörgensen; M D Nielsen; J O Lund; O Munck
Journal:  Scand J Clin Lab Invest       Date:  1970-12       Impact factor: 1.713

4.  Plasma noradrenaline and adrenaline in patients with thyrotoxicosis and myxoedema.

Authors:  N J Christensen
Journal:  Clin Sci Mol Med       Date:  1973-08

5.  [Effect of BAY a 1040 on renal function in hypertension].

Authors:  K Klütsch; P Schmidt; J Grosswendt
Journal:  Arzneimittelforschung       Date:  1972-02

6.  Acute and chronic effects of nifedipine in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

7.  Changes in plasma volume and extracellular fluid volume and after addition of hydralazine to propranolol treatment in patients with hypertension.

Authors:  H Ibsen; K Rasmussen; H A Jensen; A Leth
Journal:  Acta Med Scand       Date:  1978

8.  Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man.

Authors:  W A Pettinger; H C Mitchell
Journal:  N Engl J Med       Date:  1975-06-05       Impact factor: 91.245

9.  Control plasma renin activity and changes in sympathetic tone as determinants of minoxidil-induced increase in plasma renin activity.

Authors:  K O'Malley; M Velasco; J Wells; J L McNay
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

10.  Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.

Authors:  K Aoki; T Yoshida; S Kato; K Tazumi; I Sato
Journal:  Jpn Heart J       Date:  1976-07
View more
  42 in total

1.  A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects.

Authors:  S Ueda; P A Meredith; C A Howie; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

2.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

4.  Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects.

Authors:  K Handa; T Mori; H Tanaka; Y Takada; A Matsunaga; A Kiyonaga; M Shindo; J Sasaki; K Arakawa
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

5.  Effects of calcium antagonists on adrenaline-induced hypokalaemia.

Authors:  A Mimran; J Ribstein; J Sissmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Nicardipine hydrochloride in essential hypertension--a controlled study.

Authors:  J Asplund
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Acute calcium entry blockade inhibits the blood pressure but not the hormonal responses to angiotensin II.

Authors:  J Staessen; R Fagard; P Hespel; P Lijnen; E Moerman; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine.

Authors:  H E Sluiter; F T Huysmans; T A Thien; R A Koene
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  [Effect of the Ca antagonist nimodipine on global and regional cerebrovascular circulation].

Authors:  M R Gaab; C P Rode; E H Schakel; I Haubitz; J Bockhorn; A Brawanski
Journal:  Klin Wochenschr       Date:  1985-01-02

10.  Determination of (+)- and (-)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine.

Authors:  T Iwaoka; N Inotsume; J Inoue; S Naomi; Y Okamoto; S Higuchi; M Nakano; T Umeda
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.